| [1] |
Chua TC, Esquivel J, Pelz JO, et al. Summary of current therapeutic options for peritoneal metastases from colorectal cancer[J]. J Surg oncol, 2013, 107(6): 566-73.
|
| [2] |
Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis[J]. J Surg oncol, 2010, 101(8): 713-24.
|
| [3] |
Glehen O, Osinsky D, Cot te E, et al. Int raperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures[J]. Ann Surg Oncol, 2003, 10(8): 863-9.
|
| [4] |
Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution[J]. Ann Oncol, 2002, 13(2): 267-72.
|
| [5] |
El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance[J]. Neoplasia, 2004, 6(2): 117-27.
|
| [6] |
Huang CQ, Feng JP, Yang X, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center[J]. J Surg Oncol, 2014, 10 9(7): 730-9.
|
| [7] |
Coccolini F, Campanati L, Catena F, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study[J]. J Gynecol Oncol, 2015, 26(1): 54-61.
|
| [8] |
Li Y, Zhou YF, Liang H, et al. Expert Consensus on the Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemothe r apy (HIPEC) to Tr e a t Pe r i tone a l Sur f a c e Malignancies[J]. Zhongguo Zhong Liu Lin Chuang, 2015, 42(4): 19 8-206. [李雁, 周云峰, 梁寒, 等. 细胞减灭术加腹腔热灌注 化疗治疗腹膜表面肿瘤的专家共识[J]. 中国肿瘤临床, 2015, 42 (4): 198-206.]
|
| [9] |
Tan YN, Yuang Y. Treatment advances of peritoneal metastasis from gastric cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(5): 50 6-10.[谭依诺，袁瑛. 胃癌腹膜转移的治疗进展[J]. 肿瘤防治 研究, 2015, 42(5): 506-10.]
|
| [10] |
Ali I, Wani WA, Saleem K, et al. Platinum compouds: a hope for future cancer chemotherapy[J]. Anticancer Agents Med Chem, 20 13, 13(2): 296-306.
|
| [11] |
Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials[J]. Dalton Trans, 2010, 39(35): 8113-27.
|
| [12] |
Peng Y, Liu YE, Ren XC, et al. A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy[J]. Oncol Lett, 2015, 9(1): 67-74.
|
| [13] |
Long GX, Lin JW, Liu DB, et al. Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients[J]. Oral Oncol, 20 14, 50(8): 712-20.
|
| [14] |
Xie CY, Xu YP, Jin W, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer[J]. Anticancer Drugs, 2012, 23(7): 698-705.
|
| [15] |
Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 20 11, 18(6): 1575-81.
|
| [16] |
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer[J]. Cancer Chemother Pharmacol, 19 99, 43 Suppl:15-25.
|
| [17] |
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis[J]. Cancer Treat Res, 1996, 82: 359-74.
|
| [18] |
National Cancer Institute: Common Terminology Criteria for Adverse Events version 4.0[EB/OL]. http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm.
|
| [19] |
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20): 3737-43.
|
| [20] |
Tang L, Mei LJ, Yang XJ, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study[J]. J Transl Med, 2011, 9: 53.
|
| [21] |
Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized PhaseⅢStudy[J]. Ann Surg Oncol, 2015, 22(5): 15 70-5.
|
| [22] |
Deng QQ, Huang XE, Ye LH, et al. PhaseⅡtrial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes[J]. Asian Pac J Cancer Prev, 2013, 14(1): 413-7.
|
| [23] |
Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma[J]. Therap Adv Gastroenterol, 2015, 8(4): 199-205.
|
| [24] |
Tan Q, Joshua AM, Saqqar JK, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy[J]. Br J Cancer, 2015, 112(5): 832-40.
|
| [25] |
Li XC, Li YH. Clinical study on chemotherapy of lobplatin combined with docetaxel in patients with relapsed ovarian cancer[J]. Zhongnan Da Xue Xue Bao (Yi Xue Ban), 2014, 39 (11): 1131-6. [李新春, 李瑛花. 洛铂联合多西他赛治疗复发 性卵巢癌的疗效[J]. 中南大学学报（医学版）, 2014, 39(11): 11 31-6.]
|
| [26] |
Zhang YH, Li Y, Chen C, et al. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy[J]. Hepatogastroenterology, 2009, 56(96): 1750-4.
|
| [27] |
Nakata B, Hirakawa-YS Chung K, Kato Y, et al. Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma[J]. Cancer, 1998, 83(12): 2488-92.
|
| [28] |
Polat E, Duman U, Duman M, et al. Preoperative serum tumor marker levels in gastric cancer[J]. Pak J Med Sci, 2014, 30(1): 14 5-9.
|
| [29] |
Scaringi S, Kianmanesh R, Sabate JM, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience[J]. Eur J Surg Oncol, 2008, 34(11): 1246-52.
|
| [30] |
Arias F, Herrera-Almario G, Pozo ME, et al. Safety and quality outcomes in peritoneal surface malignancy patients: developing a national center for excellence in Colombia[J]. Ann Surg Oncol, 20 15, 22(5): 1733-8.
|
下载:
